Chang Hyo Yoon1, Yoon Kyung Park1, Suk Jae Kim1, Mi-ji Lee1, Sookyung Ryoo1, Gyeong-Moon Kim1, Chin-Sang Chung1, Kwang Ho Lee1, June Soo Kim1, Oh Young Bang2. 1. From the Department of Neurology (C.H.Y., Y.K.P., S.J.K., M.-j.L., S.R., G.-M.K., C.-S.C., K.H.L., O.Y.B.) and Department of Cardiology (J.S.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 2. From the Department of Neurology (C.H.Y., Y.K.P., S.J.K., M.-j.L., S.R., G.-M.K., C.-S.C., K.H.L., O.Y.B.) and Department of Cardiology (J.S.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. neuroboy50@naver.com.
Abstract
BACKGROUND AND PURPOSE: Recent randomized clinical trials (RCTs) have evaluated the benefit of new oral anticoagulants in reducing the risk of vascular events and bleeding complications in patients with atrial fibrillation (AF). However, abundant and strict enrollment criteria may limit the validity and applicability of results of RCTs to clinical practice. We estimated the eligibility for participation in RCTs of an unselected group of patients with AF. In addition, we compared features favoring new oral anticoagulant use between patients with versus without stroke. Randomized Evaluation of Long-Term Anticoagulation Therapy METHODS: We applied enrollment criteria of 4 RCTs (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) to 695 patients with AF taking warfarin, prospectively and consecutively collected at a university medical center; 500 patients with and 195 patients without stroke. Time in therapeutic range and bleeding risk scheme (anticoagulation and risk factors in atrial fibrillation) were also measured. RESULTS: The proportions of patients fulfilling the trial enrollment criteria varied, ranging from 39% to 72.8%, depending on the differences in indications/contraindications among studies and presence/absence of stroke. The main reasons for ineligibility for RCTs were hemorrhagic risk (anticoagulation and risk factors in atrial fibrillation [ATRIA] score) (10.8%-40.5%) and planned cardioversion (5.1%-7.7%) for nonstroke patients, and a low creatinine clearance (5.6%-9.2%) and higher risk of bleeding (15.2%-20.8%) for patients with stroke. When compared with nonstroke patients, patients with stroke showed a lower time in therapeutic range (54.4±42.8% versus 65.4±34.9%, especially with severe disability) and a high hemorrhagic risk (ATRIA score) (3.06±2.30 versus 2.18±2.16) (P<0.05 in both cases). CONCLUSIONS: Patients enrolled in RCTs are partly representative of patients with AF in clinical practice. When time in therapeutic range and bleeding tendency with warfarin use were considered, the use of new oral anticoagulants was preferred in patients with stroke than in nonstroke patients, but they were more likely to be excluded in RCTs.
BACKGROUND AND PURPOSE: Recent randomized clinical trials (RCTs) have evaluated the benefit of new oral anticoagulants in reducing the risk of vascular events and bleeding complications in patients with atrial fibrillation (AF). However, abundant and strict enrollment criteria may limit the validity and applicability of results of RCTs to clinical practice. We estimated the eligibility for participation in RCTs of an unselected group of patients with AF. In addition, we compared features favoring new oral anticoagulant use between patients with versus without stroke. Randomized Evaluation of Long-Term Anticoagulation Therapy METHODS: We applied enrollment criteria of 4 RCTs (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) to 695 patients with AF taking warfarin, prospectively and consecutively collected at a university medical center; 500 patients with and 195 patients without stroke. Time in therapeutic range and bleeding risk scheme (anticoagulation and risk factors in atrial fibrillation) were also measured. RESULTS: The proportions of patients fulfilling the trial enrollment criteria varied, ranging from 39% to 72.8%, depending on the differences in indications/contraindications among studies and presence/absence of stroke. The main reasons for ineligibility for RCTs were hemorrhagic risk (anticoagulation and risk factors in atrial fibrillation [ATRIA] score) (10.8%-40.5%) and planned cardioversion (5.1%-7.7%) for nonstroke patients, and a low creatinine clearance (5.6%-9.2%) and higher risk of bleeding (15.2%-20.8%) for patients with stroke. When compared with nonstroke patients, patients with stroke showed a lower time in therapeutic range (54.4±42.8% versus 65.4±34.9%, especially with severe disability) and a high hemorrhagic risk (ATRIA score) (3.06±2.30 versus 2.18±2.16) (P<0.05 in both cases). CONCLUSIONS:Patients enrolled in RCTs are partly representative of patients with AF in clinical practice. When time in therapeutic range and bleeding tendency with warfarin use were considered, the use of new oral anticoagulants was preferred in patients with stroke than in nonstroke patients, but they were more likely to be excluded in RCTs.
Authors: Alexandros A Polymeris; Annaelle Zietz; Fabian Schaub; Louisa Meya; Christopher Traenka; Sebastian Thilemann; Benjamin Wagner; Lisa Hert; Valerian L Altersberger; David J Seiffge; Flurina Lyrer; Tolga Dittrich; Ines Piot; Josefin Kaufmann; Lea Barone; Ludvig Dahlheim; Sophie Flammer; Nikolaos S Avramiotis; Nils Peters; Gian Marco De Marchis; Leo H Bonati; Henrik Gensicke; Stefan T Engelter; Philippe A Lyrer Journal: Eur Stroke J Date: 2022-05-10
Authors: Wei-Hsuan Lo-Ciganic; Walid F Gellad; Haiden A Huskamp; Niteesh K Choudhry; Chung-Chou H Chang; Ruoxin Zhang; Bobby L Jones; Hasan Guclu; Seth Richards-Shubik; Julie M Donohue Journal: Med Care Date: 2016-07 Impact factor: 2.983
Authors: David J Seiffge; Maurizio Paciaroni; Duncan Wilson; Masatoshi Koga; Kosmas Macha; Manuel Cappellari; Sabine Schaedelin; Clare Shakeshaft; Masahito Takagi; Georgios Tsivgoulis; Bruno Bonetti; Bernd Kallmünzer; Shoji Arihiro; Andrea Alberti; Alexandros A Polymeris; Gareth Ambler; Sohei Yoshimura; Michele Venti; Leo H Bonati; Keith W Muir; Hiroshi Yamagami; Sebastian Thilemann; Riccardo Altavilla; Nils Peters; Manabu Inoue; Tobias Bobinger; Giancarlo Agnelli; Martin M Brown; Shoichiro Sato; Monica Acciarresi; Hans Rolf Jager; Paolo Bovi; Stefan Schwab; Philippe Lyrer; Valeria Caso; Kazunori Toyoda; David J Werring; Stefan T Engelter; Gian Marco De Marchis Journal: Ann Neurol Date: 2019-04-30 Impact factor: 10.422
Authors: Gustavo Zapata-Wainberg; Sonia Quintas; Álvaro Ximénez-Carrillo Rico; Jaime Masjuán Vallejo; Pere Cardona; Mar Castellanos Rodrigo; Lorena Benavente Fernández; Andrés García Pastor; José Egido; José Maciñeiras; Joaquín Serena; María Del Mar Freijo Guerrero; Francisco Moniche; José Vivancos Journal: Interv Neurol Date: 2018-04-04